These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 21164498)

  • 1. Urinary albumin excretion during angiotensin II receptor blockade: comparison of combination treatment with a diuretic or a calcium-channel blocker.
    Matsui Y; Eguchi K; Ishikawa J; Shimada K; Kario K
    Am J Hypertens; 2011 Apr; 24(4):466-73. PubMed ID: 21164498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T; Numabe A; Masuda T; Akabane T; Okamura A; Minami J; Matsuoka H
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of combination therapies, including the angiotensin receptor blocker olmesartan and either a calcium channel blocker or a thiazide diuretic, in elderly patients with hypertension.
    Kato J; Yokota N; Tamaki N; Kariya S; Kita T; Ayabe T; Eto T; Kitamura K
    Hypertens Res; 2011 Mar; 34(3):331-5. PubMed ID: 21124326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y; O'Rourke MF; Hoshide S; Ishikawa J; Shimada K; Kario K
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M; Okubo S; Mizubayashi R; Isaka N; Machida H; Okamoto S; Hirota H; Takeuchi M; Kato T; Nakatani K; Mizuno O; Miyagawa K; Makino K; Okura T; Dohi Y; Ito M; Kimura G
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
    Iwai M; Chen R; Ide A; Iwanami J; Tomochika H; Tomono Y; Mogi M; Horiuchi M
    J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy.
    Ogawa S; Mori T; Nako K; Ito S
    Hypertens Res; 2008 Jun; 31(6):1147-55. PubMed ID: 18716362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients.
    Matsui Y; Eguchi K; O'Rourke MF; Ishikawa J; Miyashita H; Shimada K; Kario K
    Hypertension; 2009 Oct; 54(4):716-23. PubMed ID: 19667251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.
    Ogihara T; Saruta T; Rakugi H; Shimamoto K; Ito S; Matsuoka H; Horiuchi M; Imaizumi T; Takishita S; Higaki J; Katayama S; Saito I; Shimada K;
    Hypertens Res; 2009 Feb; 32(2):163-7. PubMed ID: 19262477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Central blood pressure under angiotensin and calcium channel blockade.
    Safar ME; Protogerou A; Blacher J
    Hypertension; 2009 Oct; 54(4):704-6. PubMed ID: 19667254
    [No Abstract]   [Full Text] [Related]  

  • 12. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S; Yagi S; Yamamoto H; Yamaguchi M; Izumida T; Noguchi Y; Inaba M; Inukai K
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H; Kikuchi F; Ishida T
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regression of glomerular and tubulointerstitial injuries by dietary salt reduction with combination therapy of angiotensin II receptor blocker and calcium channel blocker in Dahl salt-sensitive rats.
    Rafiq K; Nishiyama A; Konishi Y; Morikawa T; Kitabayashi C; Kohno M; Masaki T; Mori H; Kobori H; Imanishi M
    PLoS One; 2014; 9(9):e107853. PubMed ID: 25233358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.
    Nagasu H; Satoh M; Yorimitsu D; Tomita N; Sasaki T; Kashihara N
    Kidney Blood Press Res; 2011; 34(2):87-96. PubMed ID: 21273789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of angiotensin II receptor antagonist with calcium channel blocker or diuretic as antihypertensive therapy for patients with chronic kidney disease.
    Ishimitsu T; Ohno E; Nakano N; Furukata S; Akashiba A; Minami J; Numabe A; Matsuoka H
    Clin Exp Hypertens; 2011; 33(6):366-72. PubMed ID: 21797795
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension: a randomized controlled trial.
    Matsuzaki M; Ogihara T; Umemoto S; Rakugi H; Matsuoka H; Shimada K; Abe K; Suzuki N; Eto T; Higaki J; Ito S; Kamiya A; Kikuchi K; Suzuki H; Tei C; Ohashi Y; Saruta T;
    J Hypertens; 2011 Aug; 29(8):1649-59. PubMed ID: 21610513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan.
    Jinno T; Iwai M; Li Z; Li JM; Liu HW; Cui TX; Rakugi H; Ogihara T; Horiuchi M
    Hypertension; 2004 Feb; 43(2):263-9. PubMed ID: 14707152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy of calcium channel blocker and angiotensin II receptor blocker reduces augmentation index in hypertensive patients.
    Doi M; Miyoshi T; Hirohata S; Kamikawa S; Usui S; Kaji Y; Sakane K; Ogawa H; Ninomiya Y; Kusachi S
    Am J Med Sci; 2010 May; 339(5):433-9. PubMed ID: 20234301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
    Shinohara K; Hirooka Y; Ogawa K; Kishi T; Yasukawa K; Utsumi H; Sunagawa K
    Clin Exp Hypertens; 2012; 34(6):456-62. PubMed ID: 22471901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.